Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia.
Int J Mol Sci. 2021 Jun 23;22(13):6741. doi: 10.3390/ijms22136741.
It is now well accepted that the immune system can control cancer growth. However, tumors escape immune-mediated control through multiple mechanisms and the downregulation or loss of major histocompatibility class (MHC)-I molecules is a common immune escape mechanism in many cancers. MHC-I molecules present antigenic peptides to cytotoxic T cells, and MHC-I loss can render tumor cells invisible to the immune system. In this review, we examine the dysregulation of MHC-I expression in cancer, explore the nature of MHC-I-bound antigenic peptides recognized by immune cells, and discuss therapeutic strategies that can be used to overcome MHC-I deficiency in solid tumors, with a focus on the role of natural killer (NK) cells and CD4 T cells.
现在人们普遍认为免疫系统可以控制癌症的生长。然而，肿瘤通过多种机制逃避免疫介导的控制，主要组织相容性复合体（MHC）-I 分子的下调或缺失是许多癌症中常见的免疫逃逸机制。MHC-I 分子向细胞毒性 T 细胞呈递抗原肽，而 MHC-I 的缺失会使肿瘤细胞对免疫系统不可见。在这篇综述中，我们研究了癌症中 MHC-I 表达的失调，探讨了免疫细胞识别的 MHC-I 结合抗原肽的性质，并讨论了可以用于克服实体瘤中 MHC-I 缺陷的治疗策略，重点讨论了自然杀伤（NK）细胞和 CD4 T 细胞的作用。
